查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878814

CAR-T細胞療法市場－全球產業規模、佔有率、趨勢、機會和預測，按產品類型、腫瘤類型、適應症、治療類型、標靶抗原、最終用戶、地區和競爭格局分類，2020-2030年預測

CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球CAR-T細胞療法市場規模為38.7億美元，預計2030年將以22.77%的複合年成長率成長至132.5億美元。嵌合抗原受體（CAR）-T細胞療法是一種先進的免疫療法，其原理是透過基因工程改造患者自身的T細胞，使其表達靶向癌細胞表面特定抗原的受體。此市場的成長主要受以下因素驅動：全球血液系統惡性腫瘤發生率的上升、CAR-T細胞療法在復發或難治性患者群體中展現出的高效性和持久療效，以及旨在拓展治療適應症和提高治療可及性的研發投入。

市場概覽
預測期 2026-2030
2024年市場規模 38.7億美元
2030年市場規模 132.5億美元
2025-2030年複合年成長率 22.77%
成長最快的細分市場 急性淋巴母細胞白血病（ALL）
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球CAR-T細胞療法市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型（Yescarta、Kymriah、Tecartus、Breyanzi、Abecma）
    • 依腫瘤類型（血液系統惡性腫瘤、實體腫瘤）
    • 依適應症（瀰漫性大B細胞淋巴瘤（DLBCL）、急性淋巴母細胞白血病（ALL）、濾泡性淋巴瘤（FL）、套細胞淋巴瘤（MCL）、其他）
    • 目標抗原（D19、BCMA（B細胞成熟抗原）、其他）
    • 按最終使用者（醫院、專科診所、門診手術中心、其他）
    • 依治療類型（單一療法、合併療法）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美CAR-T細胞療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲CAR-T細胞療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區CAR-T細胞療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲CAR-T細胞療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美CAR-T細胞療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球CAR-T細胞療法市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Gilead Sciences, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Cellectis SA
  • Amgen Inc.
  • Pfizer Inc
  • Merck KgaA
  • Intellia Therapeutics, Inc.
  • Johnson & Johnson

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 5168

The Global CAR-T Cell Therapy Market, valued at USD 3.87 Billion in 2024, is projected to experience a CAGR of 22.77% to reach USD 13.25 Billion by 2030. Chimeric Antigen Receptor (CAR)-T cell therapy represents an advanced form of immunotherapy where a patient's T cells are genetically engineered to express a receptor targeting specific antigens on cancer cells. The market's expansion is primarily driven by the increasing global incidence of hematological malignancies, the demonstrated high efficacy and durable responses observed in relapsed or refractory patient populations, and substantial investment in research and development aimed at broadening therapeutic indications and enhancing treatment accessibility.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.87 Billion
Market Size 2030USD 13.25 Billion
CAGR 2025-203022.77%
Fastest Growing SegmentAcute Lymphoblastic Leukemia (ALL)
Largest MarketNorth America

Key Market Drivers

The global CAR-T cell therapy market is significantly influenced by the demonstrated high efficacy of these treatments in hematologic malignancies and the expanding regulatory approvals for new indications. The proven ability of CAR-T therapies to induce deep and durable responses in patient populations with limited alternative options provides a compelling clinical rationale for their adoption and growth. For instance, according to Bristol Myers Squibb and 2seventy bio, in February 2023, the Phase 3 KarMMa-3 study demonstrated that Abecma achieved a 71% overall response rate in patients with relapsed or refractory multiple myeloma. This robust clinical performance underscores the transformative potential of CAR-T cells, driving demand and investment in this therapeutic area.

Key Market Challenges

The substantial cost associated with personalized CAR-T cell treatments represents a significant barrier to the global market's expansion. These high costs severely limit broader patient access and place considerable strain on healthcare systems, directly impeding the widespread adoption of these therapies. The financial burden creates substantial hurdles for both patients and healthcare providers, restricting the volume of treatments administered.

Key Market Trends

Expansion into Solid Tumor Indications represents a crucial diversification beyond the initial successes in hematologic malignancies, opening significant new market segments. The inherent complexities of solid tumors, such as their immunosuppressive microenvironments and heterogeneous antigen expression, have historically presented considerable challenges for CAR-T cell efficacy. However, ongoing research and technological innovations are addressing these barriers through enhanced CAR designs, localized delivery methods, and combinatorial approaches. Progress in this area is evidenced by the growing number of clinical investigations, with solid tumors constituting 24.6% of CAR-T clinical trials as of May 2025, according to insights from Frontiers. This expansion into a broader range of cancer types is pivotal for realizing the full therapeutic and commercial potential of CAR-T cell therapy, moving it towards a more widespread application in oncology.

Key Market Players

  • Gilead Sciences, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Cellectis SA
  • Amgen Inc.
  • Pfizer Inc
  • Merck KgaA
  • Intellia Therapeutics, Inc.
  • Johnson & Johnson

Report Scope:

In this report, the Global CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CAR-T Cell Therapy Market, By Product Type:

  • Yescarta
  • Kymriah
  • Tecartus
  • Breyanzi
  • Abecma

CAR-T Cell Therapy Market, By Tumor Type:

  • Hematological Malignancies
  • Solid Tumors

CAR-T Cell Therapy Market, By Indication:

  • Diffused Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Others

CAR-T Cell Therapy Market, By Targeted Antigen:

  • D 19
  • BCMA (B-Cell Maturation Antigen)
  • Others

CAR-T Cell Therapy Market, By End User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

CAR-T Cell Therapy Market, By Treatment Type:

  • Single Treatment
  • Combination Treatment

CAR-T Cell Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global CAR-T Cell Therapy Market.

Available Customizations:

Global CAR-T Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CAR-T Cell Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Yescarta, Kymriah, Tecartus, Breyanzi, Abecma)
    • 5.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
    • 5.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
    • 5.2.4. By Targeted Antigen (D 19, BCMA (B-Cell Maturation Antigen), Others)
    • 5.2.5. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.6. By Treatment Type (Single Treatment, Combination Treatment)
    • 5.2.7. By Region
    • 5.2.8. By Company (2024)
  • 5.3. Market Map

6. North America CAR-T Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Tumor Type
    • 6.2.3. By Indication
    • 6.2.4. By Targeted Antigen
    • 6.2.5. By End User
    • 6.2.6. By Treatment Type
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States CAR-T Cell Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Tumor Type
        • 6.3.1.2.3. By Indication
        • 6.3.1.2.4. By Targeted Antigen
        • 6.3.1.2.5. By End User
        • 6.3.1.2.6. By Treatment Type
    • 6.3.2. Canada CAR-T Cell Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Tumor Type
        • 6.3.2.2.3. By Indication
        • 6.3.2.2.4. By Targeted Antigen
        • 6.3.2.2.5. By End User
        • 6.3.2.2.6. By Treatment Type
    • 6.3.3. Mexico CAR-T Cell Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Tumor Type
        • 6.3.3.2.3. By Indication
        • 6.3.3.2.4. By Targeted Antigen
        • 6.3.3.2.5. By End User
        • 6.3.3.2.6. By Treatment Type

7. Europe CAR-T Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Tumor Type
    • 7.2.3. By Indication
    • 7.2.4. By Targeted Antigen
    • 7.2.5. By End User
    • 7.2.6. By Treatment Type
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany CAR-T Cell Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Tumor Type
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By Targeted Antigen
        • 7.3.1.2.5. By End User
        • 7.3.1.2.6. By Treatment Type
    • 7.3.2. France CAR-T Cell Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Tumor Type
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By Targeted Antigen
        • 7.3.2.2.5. By End User
        • 7.3.2.2.6. By Treatment Type
    • 7.3.3. United Kingdom CAR-T Cell Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Tumor Type
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By Targeted Antigen
        • 7.3.3.2.5. By End User
        • 7.3.3.2.6. By Treatment Type
    • 7.3.4. Italy CAR-T Cell Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Tumor Type
        • 7.3.4.2.3. By Indication
        • 7.3.4.2.4. By Targeted Antigen
        • 7.3.4.2.5. By End User
        • 7.3.4.2.6. By Treatment Type
    • 7.3.5. Spain CAR-T Cell Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Tumor Type
        • 7.3.5.2.3. By Indication
        • 7.3.5.2.4. By Targeted Antigen
        • 7.3.5.2.5. By End User
        • 7.3.5.2.6. By Treatment Type

8. Asia Pacific CAR-T Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Tumor Type
    • 8.2.3. By Indication
    • 8.2.4. By Targeted Antigen
    • 8.2.5. By End User
    • 8.2.6. By Treatment Type
    • 8.2.7. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China CAR-T Cell Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Tumor Type
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By Targeted Antigen
        • 8.3.1.2.5. By End User
        • 8.3.1.2.6. By Treatment Type
    • 8.3.2. India CAR-T Cell Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Tumor Type
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By Targeted Antigen
        • 8.3.2.2.5. By End User
        • 8.3.2.2.6. By Treatment Type
    • 8.3.3. Japan CAR-T Cell Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Tumor Type
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By Targeted Antigen
        • 8.3.3.2.5. By End User
        • 8.3.3.2.6. By Treatment Type
    • 8.3.4. South Korea CAR-T Cell Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Tumor Type
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By Targeted Antigen
        • 8.3.4.2.5. By End User
        • 8.3.4.2.6. By Treatment Type
    • 8.3.5. Australia CAR-T Cell Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Tumor Type
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By Targeted Antigen
        • 8.3.5.2.5. By End User
        • 8.3.5.2.6. By Treatment Type

9. Middle East & Africa CAR-T Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Tumor Type
    • 9.2.3. By Indication
    • 9.2.4. By Targeted Antigen
    • 9.2.5. By End User
    • 9.2.6. By Treatment Type
    • 9.2.7. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia CAR-T Cell Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Tumor Type
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By Targeted Antigen
        • 9.3.1.2.5. By End User
        • 9.3.1.2.6. By Treatment Type
    • 9.3.2. UAE CAR-T Cell Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Tumor Type
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By Targeted Antigen
        • 9.3.2.2.5. By End User
        • 9.3.2.2.6. By Treatment Type
    • 9.3.3. South Africa CAR-T Cell Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Tumor Type
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By Targeted Antigen
        • 9.3.3.2.5. By End User
        • 9.3.3.2.6. By Treatment Type

10. South America CAR-T Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Tumor Type
    • 10.2.3. By Indication
    • 10.2.4. By Targeted Antigen
    • 10.2.5. By End User
    • 10.2.6. By Treatment Type
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil CAR-T Cell Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Tumor Type
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By Targeted Antigen
        • 10.3.1.2.5. By End User
        • 10.3.1.2.6. By Treatment Type
    • 10.3.2. Colombia CAR-T Cell Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Tumor Type
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By Targeted Antigen
        • 10.3.2.2.5. By End User
        • 10.3.2.2.6. By Treatment Type
    • 10.3.3. Argentina CAR-T Cell Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Tumor Type
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By Targeted Antigen
        • 10.3.3.2.5. By End User
        • 10.3.3.2.6. By Treatment Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global CAR-T Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Gilead Sciences, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Bristol-Myers Squibb Company
  • 15.4. AbbVie Inc.
  • 15.5. Cellectis SA
  • 15.6. Amgen Inc.
  • 15.7. Pfizer Inc
  • 15.8. Merck KgaA
  • 15.9. Intellia Therapeutics, Inc.
  • 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer